儿童获取受管制药物:政策教训,干预优先事项和行动框架
Maria-Belen Tarrafeta-Sayas1, Brandon Maser2, Ximena García-Quintero3
1Department of Public Health, Institute of Tropical Medicine, Antwerp, Antwerp Province, Belgium.
The Lancet. Child & adolescent health
|February 21, 2026
概括
低收入国家的儿童面临着严重的障碍,无法获得必要的受控药物. 这项研究提供了政策解决方案和框架,以改善儿童群体对这些重要药物的公平获取.
科学领域:
- 卫生政策 卫生政策
- 全球健康 全球健康
- 药品接入 药品接入 药品接入
背景情况:
- 低收入和中等收入国家 (LMICs) 的儿童在获取受管制药物方面面临重大挑战.
- 对于儿科控制药物获取现有的障碍,需要全面的,政策驱动的,系统级干预措施.
- 有必要研究有效的政策策略来解决这一全球不平等问题.
研究的目的:
- 审查关于改善儿童获得受管制药物的政策指导和资源.
- 突出从LMIC (乌干达,印度,哥斯达黎加) 中可以转移的政策教训.
- 提出研究和干预优先事项以及可操作杆的框架.
主要方法:
- 对相关政策指导和资源进行有目的的审查.
- 分析三个低收入和中等收入国家的政策教训.
- 综合文献和多学科专家的意见.
主要成果:
- 确定了改善访问的关键政策教训和可操作的杆.
- 制定了一个功能框架,概述了加强儿科控制药物获取的战略.
- 强调了特定于环境,系统层面的政策干预的重要性.
结论:
- 解决儿童控制药物获取的全球不平等问题需要有针对性的政策和系统层面的方法.
- 可转移的政策教训和专家指导对于开发有效干预措施至关重要.
- 拟议的框架提供了可行的步骤,以改善儿童适当获得受管制药物的机会.
相关概念视频
Drug Control Governance: Regulatory Bodies and Their Impact
612
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
612
Pharmaceutical Poisoning: Potential Scenarios
22
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
22
Pharmacokinetics in Pediatric Patients: Drug Distribution
356
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
356
Prescription, Nonprescription and Orphan Drugs
1.3K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.3K
Pharmacokinetics in Pediatric Patients: Drug Metabolism
276
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276
Pharmacokinetics in Pediatric Patients: Drug Excretion
302
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
302


